Sermorelin: the older growth hormone peptide that still has defenders

You’ve seen the ad. Restore the growth hormone of your twenties. Sleep deeper. Wake sharper. Trim a little fat without changing what you eat. The peptide on the prescription pad is usually sermorelin.

Here’s what the ad doesn’t say. Sermorelin actually cleared the FDA twice — first as a diagnostic, then as a treatment for pediatric growth hormone deficiency. Neither approval was for tightening up a forty-year-old’s body composition. The brand it was sold under is gone. The molecule survives because compounding pharmacies kept making it, and a particular kind of anti-aging clinic kept prescribing it.

That history is the reason sermorelin gets called the legitimate one. It’s not wrong, exactly. It’s just the most generous possible reading of a story that gets a lot less flattering when you look at what’s actually been studied in healthy adults.

Why sermorelin keeps showing up

Most peptides on the longevity menu are research chemicals dressed up in clinical language. Sermorelin is the rare one that genuinely cleared the FDA.

It’s a 29-amino-acid synthetic peptide — the first 29 residues of your own growth hormone-releasing hormone (GHRH 1-44), the hypothalamic signal that tells the pituitary to release GH. The native hormone is 44 amino acids; sermorelin keeps only the active binding fragment. It hits the GHRH receptor on pituitary somatotroph cells and asks them to pulse out GH, the way your body normally would.

That mechanism is the cleaner pitch. Unlike injecting straight recombinant GH — which floods the system above natural peaks and shuts down your own pulsatility — sermorelin works upstream. The pituitary still decides. The pulse pattern stays roughly intact. For a clinician worried about the downsides of exogenous GH, that’s a meaningful difference.

It also has the regulatory record. Sermorelin was sold as Geref, manufactured by Serono, under two separate FDA applications — NDA 019863 for the low-strength diagnostic product approved in December 1990, and NDA 020443 for the higher-strength therapeutic product for idiopathic GH deficiency in children, approved in September 1997. Serono pulled both from the US market in 2008 for commercial reasons — not safety or efficacy, as the FDA later formally confirmed when it withdrew the approvals in June 2009 — as demand for the diagnostic fell. After withdrawal it stayed available through compounding pharmacies, and anti-aging endocrinology kept it on the menu.

So the defender case writes itself. Real molecule. Real approval. Real history. The compound itself has more standing than any other peptide in this conversation.

The catch is the population. Geref was approved in deficient children. The people buying sermorelin now are healthy adults in their forties and fifties whose GH is age-lower but not clinically deficient. The clinical evidence that earned the approval doesn’t transfer cleanly across that gap, and the published evidence in the new population is thinner than the marketing suggests.

What the older-adult evidence actually shows

The clinical record in healthy older adults is genuinely small and genuinely old.

A 1997 study in Metabolism by Vittone and colleagues gave single nightly subcutaneous injections of GHRH (1-29) — strict sermorelin — to healthy elderly men and asked whether the age-related decline in GH and IGF-1 could be nudged upward by hitting the receptor. It could. Modestly. The GH/IGF-1 numbers moved.

A longer-term 1997 paper in the Journal of Clinical Endocrinology and Metabolism by Khorram, Laughlin and Yen extended that with the [Nle27]GHRH-(1-29)-NH2 variant — a stabilised sermorelin analog with a single norleucine substitution — in age-advanced men and women over a sustained dosing period. Again the endocrine and metabolic effects moved in the expected direction.

Read those two studies the way they actually read. Small samples. Older adults specifically, not healthy adults in general. Months, not years. And the endpoints they measured were biomarkers — GH pulses, IGF-1, body composition shifts — not the things the marketing actually sells. Nobody in either study lived longer. Nobody got measurably sharper. Nobody trained harder. The conclusion was we can move the dial on GH/IGF-1, which is what you’d expect when you give people a GHRH agonist. Whether moving that dial meant anything about their lives is a question those studies didn’t answer.

The structural footnote matters too. The Khorram paper used the Nle27 analog, not strict sermorelin. The cleaner statement when citing this is a stabilised sermorelin analog rather than sermorelin itself. That kind of detail gets ironed out in the marketing copy. Hold onto it.

The one cognitive trial everyone leans on

This is where the conversation has to slow down.

The single most-cited piece of evidence for sermorelin helps healthy adults is a 2012 trial in Archives of Neurology by Baker and colleagues. It’s a real randomised, double-blind, placebo-controlled study. 152 adults aged 55 to 87 — 66 with mild cognitive impairment and 86 cognitively healthy at baseline. Twenty weeks of nightly self-administered subcutaneous injections of a GHRH analog at the standard study dose. Cognition was measured with standard batteries — executive function, verbal memory, visual memory.

The intent-to-treat analysis came back with a favorable cognition effect at P=.03. The completer analysis pointed the same direction. The effect was comparable in the MCI patients and the healthy older adults. It is, on its face, the kind of result the anti-aging case wants.

Read the methods section, though, and one detail does almost all the work.

The injection was tesamorelin, not sermorelin.

Tesamorelin is also a GHRH analog. It’s structurally close to sermorelin, with stabilising modifications that extend half-life. It’s the same upstream lever — GHRH-receptor agonism on the pituitary. It is not, strictly speaking, the same molecule. That distinction is the kind of thing the Khorram structural footnote already prepared you for, and it lands here too.

So the honest reading. GHRH-receptor stimulation produced a real cognitive signal in older adults in a single well-designed trial. That signal was real enough to publish in Archives of Neurology and real enough to follow up with biomarker work in 2018 by Winston, Goetzl and colleagues — which showed treatment modulation of some synaptic protein markers (synaptophysin, synaptotagmin) in plasma exosomes, but no movement in amyloid or phosphorylated tau. Some pathway engagement. No shift in the proteins most associated with Alzheimer’s pathology.

That’s the strongest case in print. One trial, sample of 152, on a closely-related GHRH analog. One follow-up. Encouraging enough that the question is being asked. Not enough to settle it.

What we know about mechanism, what we don’t know about benefit

The mechanistic case for GHRH in age-related decline has had a small renaissance.

A 2026 paper in Cell Death and Disease by Pedrolli, Granata and colleagues gave GHRH and a GHRH-receptor agonist to rat hippocampal neural stem cells and human neuroblastoma cells under amyloid-β stress. The peptide promoted cell survival, reduced amyloid-induced neurotoxicity, and engaged the cAMP/PKA/CREB, ERK1/2, and PI3K/Akt signaling pathways. It reduced GSK-3β activity and tau phosphorylation. In rat brain slices and cultured human cells.

That is a plausible mechanism story. The same receptor sermorelin hits, plus its analogs, shows neuroprotective signaling in models of the disease the marketing keeps gesturing at. It is also, strictly, in cells in a dish and rodent brain.

The brand-voice version of the science is: GHRH-receptor stimulation has a coherent biological story in age-related cognitive decline. The honest version: that story is built mostly out of preclinical biology and a single human trial on a related compound. The 2026 Frontiers in Aging review by Mavrych and colleagues reaches the same conclusion explicitly, and flags the same gaps — no agreement on dosing, no validated efficacy biomarkers, no controlled evidence for combination protocols.

That review, and the 2026 Am J Sports Med primer by Mayfield and colleagues, are the current state of the field’s own take. Neither says sermorelin works for what it’s being prescribed. Both say there’s a mechanistic case and a thin evidence base.

The bridge from moves the GH axis to will let you sleep better, train harder, and look like you did a decade ago is the bridge nobody has actually built in a trial.

The regulatory edge sermorelin still has

Sermorelin’s regulatory situation is genuinely unusual.

It is not on the PCAC July 23–24, 2026 agenda. The Federal Register notice names seven substances across the two days — BPC-157, KPV, TB-500, and MOTs-C on July 23, then Emideltide (DSIP), Semax, and Epitalon on July 24 — and sermorelin isn’t among them. Because sermorelin’s active ingredient already cleared the FDA twice (Geref, NDAs 019863 and 020443), it operates under the established pharmaceutical and compounding framework, not the bulk substances process the docketed compounds are sitting in.

That matters for the legitimate framing. The other peptides on the longevity menu are awaiting a regulatory verdict that could change their availability overnight. Sermorelin already has one. Its compounded availability isn’t contingent on what PCAC decides this July. Whatever the committee lands on for the bulk peptides, sermorelin keeps doing what it’s been doing.

WADA is the other story. The 2026 S2 prohibited list — peptide hormones, growth factors, related substances and mimetics — covers GHRH analogs including sermorelin. The literal name isn’t always spelled out on the annual list; the category language reaches it. If you compete, treat it as prohibited, in and out of competition.

What would actually settle the sermorelin question

The honest endpoint isn’t can sermorelin raise IGF-1 in a 65-year-old man. We’ve known the answer to that since 1997. The harder questions are the ones nobody has run.

A controlled trial in healthy adults — the actual population buying this — with outcomes that matter. Not GH pulses. Body composition over a year. Functional fitness. Subjective sleep quality measured with the instruments sleep researchers actually use, not the patient-reported energy bumps that fill testimonial sections.

Independent replication of the Baker 2012 cognitive signal in strict sermorelin, not a closely-related analog, in a population that isn’t already cognitively impaired. The single positive trial was on a stabilised cousin of the molecule. One trial in a related compound is a starting point, not a conclusion.

A serious look at what years of GHRH-receptor stimulation does in adults whose GH is already in normal range for their age. The trials we have were weeks to months. People prescribed sermorelin for anti-aging often stay on it for years. The long arc of that has not been studied.

And a straight answer on whether the trade-off — modestly elevated IGF-1 across a long period — is worth whatever the long-term effects of that are on cell proliferation. IGF-1 isn’t just a fitness biomarker. It’s a growth signal, and growth signals in older adults are a more complicated bet than the marketing makes them out to be.

Some of those answers may come from continued work by the groups still publishing in this space. Most of them won’t, unless somebody decides to fund a large healthy-adult trial with hard endpoints — and there’s no obvious commercial reason to pay for one when the compounded prescription pad is already open.

Which leaves you, the person reading the ad, with the same gap you started with. Real molecule. Real history. Modest evidence in older adults on biomarkers. One promising cognitive trial in a closely-related compound. Encouraging mechanism work in cells. No proof of the lifestyle outcomes the marketing keeps describing. And the regulatory standing to keep being prescribed regardless.

That’s the genuine case for sermorelin in 2026. It’s more than most peptides have. It’s less than the ad implies.

Where sermorelin lands today

Sermorelin is the one peptide in this cluster whose availability isn’t waiting on the FDA’s July vote. The active ingredient already cleared the agency twice. That doesn’t make it work in healthy adults. It does mean a legitimate version of the molecule is closer than it is for the compounds still on the docket.

Wolverine Health is being built so that the legitimate version is what shows up when you order. Physician-supervised peptide service, real prescriptions, US-licensed compounding pharmacies, every batch third-party tested. We’re not selling you ahead of the science — including the science that says we don’t yet know whether stimulating GHRH does anything useful for a healthy forty-year-old over years. Join the waitlist if you want a heads-up the moment that version is available.